NextCure, Inc. and its partner Simcere Zaiming Pharmaceutical Co., Ltd. have begun the dose‑optimization phase of the Phase 1 study of SIM0505, a CDH6‑targeted antibody‑drug conjugate (ADC) for patients with platinum‑resistant ovarian cancer. The new phase is designed to refine dose selection and further de‑risk the program’s progression to registration studies.
The trial now includes additional sites in the United States and China, and new sites in Canada and Europe, expanding the geographic footprint to accelerate enrollment and data collection. This expansion is part of a strategy to present Phase 1 results at the 2026 American Society of Clinical Oncology (ASCO) conference in Chicago.
The dose‑optimization effort is a critical milestone that could shape the timing and design of subsequent pivotal trials and potential partnership discussions. By establishing an optimal dosing regimen, NextCure aims to reduce uncertainty and support regulatory and commercial advancement.
NextCure holds global rights to SIM0505 outside of China, Hong Kong, Macau, and Taiwan, where Simcere Zaiming retains rights. The partnership leverages Simcere’s manufacturing and regulatory capabilities in China and the broader global reach of NextCure.
The company’s financial profile shows a net loss of $55.8 million for 2025, comparable to $55.7 million in 2024, and a Q1 2025 net loss of $11.0 million versus $17.1 million in Q1 2024. Cash reserves are expected to fund operations through the second half of 2026 and potentially into the first half of 2027, providing a runway for the SIM0505 program.
SIM0505 has received FDA Fast Track designation for platinum‑resistant ovarian cancer, positioning it for expedited development. The drug competes with other CDH6‑targeting ADCs, notably Raludotatug deruxtecan (R‑DXd) from Daiichi Sankyo and Merck, which has Breakthrough Therapy designation for similar indications.
CEO Michael Richman emphasized the company’s focus on delivering the ADC to patients quickly while ensuring robust safety and efficacy data. The dose‑optimization phase is a key step toward that goal and signals confidence in the program’s potential to address an unmet need in platinum‑resistant ovarian cancer.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.